Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010) - Concepedia

Concepedia

Publication | Open Access

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

DOI Full Paper Access

30

Citations

16

References

2023

Year

Alistair Ring, Lucy Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr, Andrew Wardley, Bora Gürel, Iain R. Macpherson, Ruth Riisnaes, Richard D. Baird,

Clinical Cancer Research

Abstract

The response rate to olaparib and ceralasertib did not meet prespecified criteria for activity in the overall evaluable population, but responses were observed in patients who would not be expected to respond to olaparib monotherapy.

References

	Year	Citations

Page 1